2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- 5.70%1-Year Change
- Shell CompaniesIndustry
HORIZON SPACE (HSPT)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Horizon Space Acquisition II Corp. (HSPT) clarified its redemption process for shareholders ahead of two upcoming meetings: a Business Combination Meeting on February 12, 2026 to vote on merging with SL BIO Ltd., and an Extension Meeting on February 13, 2026 to vote on extending the deadline for completing the initial business combination. Shareholders who previously elected redemption in connection with the Business Combination Meeting must instruct the transfer agent by February 11, 2026 to ensure redemption in either scenario.
02/03/2026, 1:00 PM • GlobeNewswire
SPAC Merger To Take SL Bio Public Through New Entity In 2026
Taiwan-based biotechnology firm SL Bio Ltd. has filed a Form F-4 to merge with Horizon Space Acquisition II Corp. (NASDAQ:HSPT), taking the company public via SPAC at an implied equity valuation of $5.7 billion. The combined entity will operate as SL Science Holding Limited under ticker SLBT, with the public listing expected in early 2026. SL Bio focuses on cellular and gene therapy technologies, immunotherapies for oncology, and exosome-based regenerative technologies.
01/09/2026, 10:41 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/01/2026
Company Profile
Horizon Space Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in New York, New York.
Key Executives
- Mingyu Li
- Min Zhai
Current Ownership Distribution
- Institutions7.3M (91.86%)
- Other609,703 (7.70%)
- Mutual Funds35,000 (0.44%)
- Insiders0 (0.00%)